Zacks Research Brokers Reduce Earnings Estimates for PBH

Posted by Brian Himes on Jun 4th, 2026

Prestige Consumer Healthcare Inc. (NYSE:PBH – Free Report) – Stock analysts at Zacks Research dropped their Q1 2027 earnings per share (EPS) estimates for Prestige Consumer Healthcare in a research note issued on Tuesday, June 2nd. Zacks Research analyst Team now anticipates that the company will post earnings per share of $0.88 for the quarter, down from their prior forecast of $1.09. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.45 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s Q1 2028 earnings at $0.96 EPS.

A number of other equities analysts have also issued reports on PBH. Weiss Ratings lowered Prestige Consumer Healthcare from a “hold (c)” rating to a “hold (c-)” rating in a report on Thursday, May 14th. Oppenheimer lowered Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. Finally, Canaccord Genuity Group lowered their price target on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Two investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $70.75.

View Our Latest Stock Report on Prestige Consumer Healthcare

Prestige Consumer Healthcare Stock Performance

NYSE PBH opened at $45.43 on Thursday. The company has a quick ratio of 2.25, a current ratio of 3.57 and a debt-to-equity ratio of 0.54. Prestige Consumer Healthcare has a 52-week low of $42.62 and a 52-week high of $87.12. The business’s 50-day moving average price is $53.69 and its 200 day moving average price is $60.16. The firm has a market cap of $2.15 billion, a P/E ratio of 11.62, a P/E/G ratio of 1.47 and a beta of 0.35.

Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) last released its quarterly earnings results on Wednesday, May 13th. The company reported $1.23 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16). Prestige Consumer Healthcare had a return on equity of 11.54% and a net margin of 17.48%.The company had revenue of $281.62 million for the quarter, compared to analysts’ expectations of $293.64 million. During the same period in the prior year, the business earned $1.32 EPS. The business’s quarterly revenue was down 5.0% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Institutional investors have recently added to or reduced their stakes in the business. Lido Advisors LLC grew its stake in shares of Prestige Consumer Healthcare by 5.4% during the 4th quarter. Lido Advisors LLC now owns 3,778 shares of the company’s stock valued at $235,000 after buying an additional 192 shares during the period. Profund Advisors LLC grew its stake in shares of Prestige Consumer Healthcare by 3.2% during the 3rd quarter. Profund Advisors LLC now owns 6,770 shares of the company’s stock valued at $422,000 after buying an additional 207 shares during the period. Cerity Partners LLC grew its stake in shares of Prestige Consumer Healthcare by 5.9% during the 2nd quarter. Cerity Partners LLC now owns 3,884 shares of the company’s stock valued at $310,000 after buying an additional 218 shares during the period. UMB Bank n.a. grew its stake in shares of Prestige Consumer Healthcare by 110.1% during the 4th quarter. UMB Bank n.a. now owns 418 shares of the company’s stock valued at $26,000 after buying an additional 219 shares during the period. Finally, Caitong International Asset Management Co. Ltd grew its stake in shares of Prestige Consumer Healthcare by 69.8% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company’s stock valued at $35,000 after buying an additional 236 shares during the period. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,207 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total value of $66,372.93. Following the sale, the vice president owned 42,820 shares of the company’s stock, valued at approximately $2,354,671.80. The trade was a 2.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.40% of the company’s stock.

Prestige Consumer Healthcare News Summary

Here are the key news stories impacting Prestige Consumer Healthcare this week:

Negative Sentiment: Zacks Research cut its FY2027 EPS estimate for Prestige Consumer Healthcare to $4.44 from $4.76, reinforcing a bearish view with a Strong Sell rating. Why Canaccord Reduced Prestige Consumer Healthcare Inc. (PBH) Price Target After Q4 Weakness
Negative Sentiment: The firm also trimmed near-term and out-year forecasts in several periods, including FY2028 EPS to $4.72 from $5.05 and Q2 2027 EPS to $1.06 from $1.14, suggesting slower earnings momentum ahead.
Negative Sentiment: Pomerantz LLP said it is investigating claims on behalf of Prestige Consumer Healthcare investors, adding potential litigation risk and another source of uncertainty for the stock. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prestige Consumer Healthcare Inc. – PBH

Prestige Consumer Healthcare Company Profile

(Get Free Report)

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).